Adalta Limited (ASX:1AD)


right-arrow Created with Sketch. -0.001 (-1.25%)
MCAP $23.76M
Last trade 15.53pm 24/01/2022 20mins delayed

Latest Announcements

24/01/2022 Price SensitivePS1ADAdalta Limited
20/01/20221ADAdalta Limited
07/01/20221ADAdalta Limited
04/01/20221ADAdalta Limited
24/12/20211ADAdalta Limited
23/12/20211ADAdalta Limited
23/12/2021 Price SensitivePS1ADAdalta Limited
23/12/20211ADAdalta Limited

Company Overview

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company’s lead candidate AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target. The i-body has also demonstrated its usefulness in treating fibrosis of the eye and is being pursued as an additional opportunity for the treatment of age-related macular degeneration (wet-AMD). The i-body is identified to have affinity and specificity with a drug target of interest, its effectiveness is evaluated in cell-based assays (in vitro) and in animal experiments (in vivo).

1AD in the news

Clinical-stage biotech company AdAlta (1AD) is looking to raise up to $5.95…
Clinical-stage drug developer AdAlta (1AD) has entered a trading halt while it…
AdAlta (1AD) is set to pocket a $4 million low-interest loan from…
AdAlta (AD1) teams up with Carina Biotech to combine their treatments to…

Search Previous Announcements